Loading...
Loading...
AVTX| Name | Value |
|---|---|
| Revenues | 0.2M |
| Cost of Revenue | -0.7M |
| Gross Profit | 1.0M |
| Operating Expense | 13.8M |
| Operating I/L | -12.9M |
| Other Income/Expense | 35.9M |
| Interest Income | 0.0M |
| Pretax | 23.0M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | 23.0M |
Avalo Therapeutics, Inc. is a clinical-stage precision medicine company specializing in targeted therapeutics for immunology, immuno-oncology, and rare genetic diseases. Their lead product, AVTX-002, is a fully human anti-LIGHT monoclonal antibody undergoing Phase II clinical trials for non-eosinophilic asthma, inflammatory bowel disease, and a Phase III trial for COVID-19 acute respiratory distress syndrome. Additionally, they are developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody for still's disease, and products for rare genetic diseases in Phase III clinical trials, including AVTX-801 for PGM1 deficiency and AVTX-803 for LADII. The company generates revenue through the development and commercialization of these targeted therapeutics.
